EUVIMEDEUVIMED entdecken
Kohortenstudie

Long‐Term Relugolix Monotherapy for Uterine Fibroids: Surgery Avoidance in a Single‐Center Retrospective Cohort Study

Yu Horibe iD, Jun Kumakiri, Tsutomu Tabata iD

Journal of Obstetrics and Gynaecology Research · 2026-11 · 52 (11)

DOI: 10.1111/jog.70553 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 30.10.2026. Verfasst von Yu Horibe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Leiomyoma, Uterine Neoplasms, Estradiol, Pyrimidinones. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Relugolix monotherapy for uterine fibroids is approved in Japan for only 180 days, and almost all long‐term evidence concerns relugolix combination therapy with estradiol and norethisterone acetate. We evaluated surgery avoidance, transition to menopause, symptom control, and bone mineral density (BMD) beyond 180 days.

Methods

We retrospectively reviewed 83 women with uterine fibroids given relugolix 40 mg monotherapy for at least 180 days at a single center between January 2015 and December 2024. Continuous variables are presented as median [interquartile range]; paired comparisons used the Wilcoxon signed‐rank test, and group comparisons used the Mann–Whitney U test and Fisher's exact test (two‐sided α = 0.05).

Results

Median treatment duration was 327 days [239.5–420.0] (maximum 1030) and median age was 43 years [37–47]. Overall, 55.4% (46/83) avoided fibroid surgery and 8.4% (7/83) reached menopause without surgery; symptoms resolved or improved in 60.2% (50/83). Among women not wishing surgery, 90.0% (27/30) avoided it, whereas 77.3% (34/44) of those wishing surgery underwent it (Fisher's exact test, p < 0.001). Uterine volume fell from 658 to 502 cm 3 (median within‐patient reduction 19.0%, p < 0.001) and maximum fibroid diameter by 7.8% ( p = 0.001). BMD trended downward at every site without reaching significance (lumbar spine −3.0%, p = 0.11). In addition, the median duration of the drug‐free period for patients who measured bone mineral density was evaluated was 726 days (range: 7–2359 days).

Conclusion

Long‐term relugolix monotherapy frequently enabled surgery avoidance and transition to menopause in women who declined surgery and controlled symptoms in most. Because estrogen add‐back is absent, BMD monitoring and a prespecified exit strategy are essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyomaUterine NeoplasmsEstradiolPyrimidinonesHumansFemaleRetrospective StudiesMiddle AgedAdultBone DensityJapan

Stichwörter der Autor:innen

bone mineral densitygonadotropin‐releasing hormone antagonistrelugolixsurgery avoidanceuterine leiomyoma

Substanzen

EstradiolPyrimidinones

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan.

ORCID-Profile: Yu Horibe, Tsutomu Tabata

Zitieren

APA

Horibe, Y., Kumakiri, J., & Tabata, T. (2026). Long‐Term Relugolix Monotherapy for Uterine Fibroids: Surgery Avoidance in a Single‐Center Retrospective Cohort Study. Journal of Obstetrics and Gynaecology Research, 52(11). https://doi.org/10.1111/jog.70553

Vancouver

Horibe Y, Kumakiri J, Tabata T. Long‐Term Relugolix Monotherapy for Uterine Fibroids: Surgery Avoidance in a Single‐Center Retrospective Cohort Study. Journal of Obstetrics and Gynaecology Research. 2026;52(11). doi:10.1111/jog.70553

BibTeX
@article{Horibe2026,
  author = {Horibe, Yu and Kumakiri, Jun and Tabata, Tsutomu},
  title = {Long‐Term Relugolix Monotherapy for Uterine Fibroids: Surgery Avoidance in a Single‐Center Retrospective Cohort Study},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  volume = {52},
  number = {11},
  doi = {10.1111/jog.70553}
}
Kostenlos starten →